Lugano-CH/Aurora-US-CO, 11 April 2012 – Abstracts submitted to the 3rd European Lung Cancer Conference (ELCC), co-organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) will be released today (12:00 CEST) and available at http://www.esmo.org/events/lung-2012-elcc/program.html. Detailed results will be presented during the ELCC 2012, 18-21 April 2012 in Geneva, Switzerland.
Three studies have been indicated as noteworthy:
Abstract 164O
First perspective pre-planned and adequately sized study for evaluation of KRAS in non-small cell lung cancer patients who seem to have a higher risk of progression
Proffered Paper session, Thursday, April 19, 14:30-16:00, Room A&B
Abstract 166O
Favorable clinical benefit of potential new therapy with dacomitinib and improvements in common disease-related symptoms
Proffered Paper session, Thursday, April 19, 14:30-16:00, Room A&B
Abstract 77O
Validation of favorable prognostic role for survival of tumor lymphocytic infiltration in resectable non-small cell lung cancer
Proffered Paper session, Friday, April 20, 14:30-16:00, Room C
Journal
Journal of Thoracic Oncology